The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS patients was evaluated in a randomized, double-blind, multicenter trial. Cidofovir (0.3% or 1%) or placebo gel was applied once daily for 5 days. Ten of 20 cidofovir-treated and none of 10 placebo-treated patients had complete healing or ú50% decreased area (P Å .008); 30% of cidofovir-treated patients versus 0 placebo recipients had complete healing (P Å .031). Viral shedding ceased in 13 (87%) of 15 cidofovir-treated and 0 of 9 placebo-treated patients (P Å .00004). For cidofovir-treated patients, median time to complete or good response was 21 days, and median time to negative viral culture was 2 days (P Å .025, P Å .0001, respectively). Median lesion area decreases were 58% for cidofovir-treated versus 0 for placebo-treated patients (P Å .005), and mean pain score changes were 01.84 versus 00.34 (P Å .042). Application site reactions occurred in 25% of cidofovir-treated and 20% of placebo-treated patients; none was dose-limiting. Cidofovir therapy provided significant benefits in lesion healing, virologic effect, and pain reduction.
Acyclovir-resistant mucocutaneous herpes simplex virus in AIDS patients with acyclovir-resistant HSV infection [3] . However, the requirement for parenteral infusion as well as the (HSV) infection has emerged as an infrequent but serious compotential toxicities of foscarnet therapy are major limitations of plication in patients with AIDS and other disorders of impaired this therapeutic modality. Trifluridine has been evaluated as a cellular immunity [1] . The majority of acyclovir-resistant HSV topical therapy. Promising results were obtained by use of clinical isolates have deficient or altered activity of the virally an ointment formulation in 3 AIDS patients with acyclovirencoded enzyme thymidine kinase [2] . These mutant strains unresponsive HSV lesions and by use of the ophthalmic soluphosphorylate acyclovir inefficiently, thereby decreasing actition in 24 such patients [4, 5] . However, clinical evaluation of vation to the active triphosphate and subsequent inhibition of trifluridine has not been subjected to controlled comparison, the viral DNA polymerase. and the available formulation is problematic because of the The only licensed therapy for the treatment of acyclovirdifficulty in applying a liquid solution evenly to mucocutaneous resistant HSV infection is parenteral foscarnet. Foscarnet, a lesions. pyrophosphate analogue that directly inhibits HSV DNA polyCidofovir (HPMPC) is a nucleotide analogue with potent in merase without requiring activation, had superior efficacy and vitro and in vivo activity against a broad range of human less toxicity than vidarabine in a comparative randomized trial herpesviruses, including HSV-1 and HSV-2 [6, 7] . Cidofovir is phosphorylated to its active metabolite by host cellular enzymes, thereby circumventing the need for activation by the 893 JID 1997; 176 (October) Cidofovir Gel for Resistant HSV application and at 30 min and, in some cases, 60 min after application.
first placebo-controlled trial evaluating therapies for this indicaCidofovir serum levels were measured by a reverse-phase high-perfortion.
mance liquid chromatography assay with UV detection [14] . The lower quantifiable limit of the assay is 220 ng/mL. Statistical analysis. A sample size of 30 patients, consisting
Methods
of 20 treated and 10 placebo patients, was planned to provide 80% Patient population. Men or women with human immunodefipower to detect a difference of 50% in response rate, that is, from ciency virus infection were eligible if they had at least one external, 60% to 10%, with a two-sided significance level of .05. The priculture-confirmed, mucocutaneous HSV lesion that was clinically mary end point of the study was the proportion of patients achievunresponsive despite at least 10 days of treatment with either oral ing complete or good (ú50%) healing of lesions during the blinded ( §1 g/day) or intravenous ( §15 mg/kg/day) acyclovir. At entry, phase of the study in the pooled cidofovir groups compared with patients were required to have a Karnofsky performance score placebo. Efficacy and safety analyses include all randomized pa- §60, serum creatinine level £152.5 mmol/L (2.0 mg/dL), absolute tients from the blinded phase of the study who received study neutrophil count §0.5 1 10 9 /L, platelet count §25 1 10 9 /L, hemodrug. Patients were censored at the time of initiation of open-label globin level §60 g/L, and negative serum pregnancy test (when therapy with cidofovir or loss to follow-up. Best response was applicable). Concurrent treatment with acyclovir, ganciclovir, foscused in the analysis irrespective of when it was achieved, in the arnet, vidarabine, trifluridine, or investigational agent(s) with poabsence of open-label cidofovir therapy. tential anti-HSV activity was prohibited, as were the use of amSince lesion size has been suggested as prognostic for outcome photericin B, immunomodulators, chemotherapeutic agents, or in previous studies [4] , the analysis for lesion response was straintravenous therapy for Pneumocystis carinii pneumonia. These tified using baseline lesion surface area as a covariate. The median agents had to have been discontinued for at least 2 weeks before baseline surface area of this sample, 1500 mm 2 , was used as a study entry, with the exception of acyclovir, which could be discutoff to define the strata. The Cochran-Mantel-Haenszel test was continued at study entry.
applied to compare response rates between treatment groups. Exact Study design and treatment. Eligible patients were randomly logistic regression (LogXact-Turbo; Turbo Cytel Software, Camassigned to 1 of 3 parallel, double-blind treatment groups: placebo bridge, MA) was used to evaluate potential predictors of response. (vehicle control), 0.3% cidofovir, or 1% cidofovir. Cidofovir was Time to response and time to negative viral culture, defined as the formulated in an aqueous propylene glycol-based gel containing first of two consecutive negative cultures, were estimated by the hydroxyethylcellulose, methylparaben, propylparaben, EDTA, and Kaplan-Meier (product-limit) method and compared by the logwater. Study drug was applied once daily for 5 consecutive days, rank test. Differences between groups in rate of conversion from followed by at least 10 days of observation. On or after day 15, positive to negative viral culture were compared by a two-tailed patients who had tolerated therapy were eligible to receive up to Fisher's exact test; patients who were culture-negative on the day six repetitive cycles of open-label treatment with 1% cidofovir gel of study entry were excluded from this analysis. over a 6-month period. Open-label therapy was permissible both
The overall pain experience of each patient during the observafor lesions that remained unhealed after the blinded study phase tion period was expressed as area under the curve of pain score, and for recurrent lesions from subsequent outbreaks.
thus representing both intensity and duration of lesion-associated The screening evaluation consisted of a medical history, physipain. The ''area under the curve minus baseline,'' or AUCMB, cal examination, laboratory tests (serum chemistries, complete analysis [15] was then applied as follows: Patients' areas under blood cell count with differential, CD4 cell count, urinalysis, and the curve were divided by the number of days between baseline pregnancy test), lesion measurement, designation of the two largest and last observation day for each patient to get a mean pain score. lesions for serial monitoring, photographs, viral culture for HSV, The baseline pain score was then subtracted from this average and patient-assessed lesion-associated 10-point pain score (0 Å no value to arrive at the AUCMB, or mean pain score change from pain, 10 Å worst pain). Serial photographs, lesion measurements, baseline. The Spearman correlation coefficient (r) was used to pain score, and assessment of adverse events were done on days assess the association between serial pain score and lesion size 1, 3, 5, 8, and 15 and once weekly thereafter. Lesion response, measurements. determined by serially calculating the sum of the product of the greatest perpendicular dimensions of the two largest lesions, was categorized as previously described: complete healing (total reResults epithelialization), good (ú50% decrease in lesion surface area), partial (between 25% and 50% decrease), and poor (õ25% deBaseline characteristics. Between November 1993 and October 1995, 33 patients were randomized, and 30 received double-blind crease, no change, or increase in lesion size) [3] .
Virologic studies. Swabs for routine viral culture were protreatment: 10 with placebo, 11 with 0.3% cidofovir gel, and 9 with 1% cidofovir gel. Each patient completed the blinded phase of the cessed at each site on days 1, 3, 5, 8, 10, 12, and 15 . Recovered isolates were referred to the Herpes Virus Research Laboratory at study without missed doses. Three patients, 1 in each treatment group, were randomized but never received study drug because of San Francisco General Hospital for in vitro susceptibility testing by plaque reduction assay in Vero cells [13] . Resistance was deineligibility, complications of AIDS, or loss to follow-up. Baseline characteristics of the 30 treated patients (26 men and fined by ID 50 §2 mg/mL for acyclovir and by ID 50 §100 mg/mL for foscarnet [13] . Resistance to cidofovir has not yet been defined. 4 women) are summarized in table 1. There were no statistically significant differences between groups in demographic variables Pharmacokinetic analysis. Serum samples for pharmacokinetic analysis were taken from a subset of patients on day 5: before gel or disease-related characteristics. The median duration of HSV infection history was 17 months (range: 1-98), the median baseand in 3 (33%) of 9 patients receiving 1% cidofovir (P Å .077 vs. placebo). For the combined cidofovir treatment groups, the line lesion surface area of marker lesions was 1500 mm 2 (range: 25-50,000), and the median number of lesions was 2 (range: complete response rate was 30% (compared with placebo, P Å .031; table 3). The median percentage of decrease in lesion area 1-11). Between placebo, 0.3% cidofovir, and 1% cidofovir groups, the difference in median baseline surface area was not statistically from baseline was 0 in placebo patients, compared with 73% in the 0.3% cidofovir group (P Å .011), 43% in the 1% cidofovir significantly different (1649, 3285, and 625 mm 2 , respectively; P Å .3; table 1). Previous foscarnet use was reported in 40%, 45%, group (P Å .026), and 58% in the combined cidofovir-treated groups (P Å .005). Analysis of potential predictors of lesion reand 22% of patients in these groups, respectively, and previous trifluridine use in 10%, 18%, and 11%.
sponse did not demonstrate an association with baseline CD4 cell count, baseline lesion area, sex, or lifetime duration of HSV infecClinical response. Complete or good healing of lesions was achieved in 0 of 10 placebo patients, compared with 10 of 20 tion (P ú .3 for all analyses). The mean change in pain score in the placebo group was 00.34 cidofovir-treated patients (P Å .008). Six (55%) of 11 patients receiving 0.3% cidofovir (P Å .007) and 4 (44%) of 9 patients (a 6% decrease comparing mean change to mean baseline pain score), compared with 02.24 (33% decrease) for the 0.3% cidoreceiving 1% cidofovir had a complete or good response (P Å .029; tables 2 and 3). The median time to complete or good response in fovir group (P Å .038), 01.34 (34% decrease) for 1% cidofovir (P Å .186), and 01.84 (34% decrease) for all cidofovir-treated the absence of open-label therapy was 21 days for cidofovir patients and was not estimable for placebo patients (P Å .025; table patients (P Å .042; table 3). Three cidofovir-treated patients had complete resolution of pain, from baseline scores of 4, 5, and 10. 3, figure 1 ). Complete healing of lesions was observed in 3 (27%) of 11 patients receiving 0.3% cidofovir (P Å .025 vs. placebo) Only 1 placebo patient had complete resolution of pain, from a baseline score of 1. Change in pain tended to correlate with change (P Å .0002) became culture-negative (table 3) . Overall, 87% of cidofovir-treated patients became viral culture-negative, comin lesion area over time (r Å .5; P Å .08).
Of the 6 patients who achieved complete healing while being pared with none in the placebo group (P Å .00004). The median times to negative culture were 4 days for the 0.3% cidofovir, 2 treated with cidofovir, response was sustained in 3 through the time of last follow-up (days 22, 51, and 57). Lesions recurred in days for the 1% cidofovir, and 2 days for the combined cidofovir groups (P Å .0007, P Å .0001, P Å .0001, respectively, compared 2 patients at 4 and 19 days, respectively, after healing was achieved. One patient, who had complete healing of lesions on with placebo; table 3, figure 2). The difference in median times to negative culture between the active treatment groups was statisday 22, could not be assessed for duration of response because of initiation of an open-label treatment with 1% cidofovir gel on that tically significant (P Å .031). Of the 10 patients who achieved complete or good lesion healsame day for new lesions.
Patients were eligible to receive open-label 1% cidofovir gel in ing, 2 continued to be culture-positive. Conversely, 5 patients receiving cidofovir did not achieve a complete or good lesion rethis protocol for any of the following reasons: poor initial response to blinded therapy, healed marker lesions but unhealed satellite sponse but became culture-negative. Baseline antiviral drug susceptibility results were available from lesions, new outbreak of herpes, or recurrence following a response. Of 21 patients who entered the open-label treatment phase 25 patient isolates during the blinded study phase (table 4) . Nineteen (76%) of the 25 isolates were resistant to acyclovir; none was for one of these reasons, 8 (38%) achieved a complete or good response.
resistant to foscarnet. A complete or good response to cidofovir was achieved in some patients with either acyclovir resistance Virologic response. None of 9 placebo patients who were viral culture-positive on the day of study entry became culture-negative (6/19 patients) or acyclovir susceptibility (3/6 patients) at study entry. An analysis of the data including only those patients with during the blinded observation period. In contrast, 7 (78%) of 9 patients in the 0.3% group (P Å .0023) and all 6 in the 1% group in vitro resistance to acyclovir at baseline continued to show supe- riority of cidofovir treatment compared with placebo; complete or Safety. Overall, 83% of patients experienced one or more adgood responses were achieved in 50% of cidofovir versus 0 placebo verse events or intercurrent illness during the blinded study phase: patients (P Å .03). Baseline cidofovir ID 50 value did not appear 80% in placebo, 91% in the 0.3% cidofovir group, and 78% in to predict response to therapy: Of 9 patients achieving a complete the 1% cidofovir group (see table 5 ). Seven patients (23%) had or good response, 5 had values greater than the median (7 mg/mL; application site reactions during the blinded study phase; all ocrange: 0.3-33 mg/mL; see table 4). curred between days 1 and 9. Two patients receiving placebo experienced pruritus or pain, 2 patients receiving 0.3% cidofovir had pain, and 3 patients receiving 1% cidofovir reported pain, Table 4 . In vitro antiviral drug susceptibility at study entry in paburning, or pruritus. None was graded as serious by the investigator tients with acyclovir-unresponsive herpes simplex virus infection.
and none was dose-limiting. Careful monitoring for systemic toxicity revealed no rises in serum creatinine of §0.5 mg/dL; protein-
uria occurred in 10% of cidofovir-treated patients and 40% of In vitro susceptibility testing showed that 6 (24%) of 25 group), and 410 ng/mL (1% group). These 3 patients had the patients entered the study with HSV isolates that were largest lesion sizes at study entry (16,900, 24,300, and 50,000 acyclovir-susceptible. Although the reason for the clinical fail- vitro testing may have failed to accurately reflect heterogeneous virus populations of acyclovir-susceptible and -resistant strains within the clinical sample. In this study, cidofovir gel was Discussion effective in patients with either acyclovir-sensitive or acyclovir-resistant disease. Also, although 3 treated patients Cidofovir is the first in a new class of nucleotide antiviral agents. Unlike nucleoside analogues, cidofovir contains a phosexperienced moderate (6-to 8-fold) rises in cidofovir ID 50 value during therapy, in no instance did posttreatment values exceed phonate group; conversion to the active triphosphate analogue in cells is done by host enzymes and is therefore independent the range of those documented before treatment. Thus, we saw no evidence of the development of resistance to cidofovir durof viral infection. By bypassing the need for virus-encoded activation, cidofovir remains effective against nucleoside-resising therapy. Safety results indicate that cidofovir gel is well-tolerated tant strains of herpesviruses [7] ; additionally, it has been shown that thymidine kinase -deficient mutants of HSV have enwithout evidence of severe local or systemic toxicity. Pharmacokinetic data suggest that systemic absorption of cidofovir gel hanced susceptibility to cidofovir compared with wild type strains because of a lesser elevation of the dCTP pool in cells was minimal and was related to lesion size. Application site reactions occurred in 25% of cidofovir-treated and 20% of infected with these strains than in those infected with wild type virus [8] . The results of this randomized, placebo-controlled, placebo patients in this study and consisted of pain, burning, and/or pruritus. In patients receiving cidofovir gel for treatment double-blind study demonstrate that cidofovir gel, in concentrations of 0.3% or 1%, applied once daily for 5 days to AIDS of other cutaneous viral infections, application site reactions have occurred in 34% of 131 patients receiving concentrations patients with acyclovir-unresponsive mucocutaneous HSV infection, provides significant benefits in lesion healing, viral of 0.3%, 1%, 3%, or 5% in varying regimens. A dose-related trend is evident. Long-term follow-up of patients receiving shedding, and pain reduction without substantial associated toxicity.
cidofovir gel has been limited. Evidence of a dose-related increase in mammary adenocarcinomas in female Sprague-DawThirty percent of cidofovir-treated patients had complete healing and an additional 20% achieved a good response ley rats receiving parenteral cidofovir suggests that this agent should be considered a potential human carcinogen. Use of (ú50% reduction in lesion size), compared with none of the patients receiving placebo gel. Given the wide range of lesion cidofovir gel for other conditions, such as for treatment of anogenital warts or molluscum contagiosum, should await the surface areas at baseline (25 -50,000 mm 2 ), the analysis of response was stratified using the median baseline surface area completion of clinical trials. This study sought to compare active cidofovir gel treatment as a covariate. However, lesion area was not a statistically significant predictor of lesion response in a post hoc analysis.
with placebo rather than comparing the two strengths of cidofovir gel. The sample size afforded õ50% power to detect The median decrease in lesion area over time, as well as the mean decrease in pain over time, were significantly greater in differences õ25% in the proportion of patients achieving complete or good response to therapy in the active treatment arms. cidofovir-treated patients than in the placebo group (P Å .005 and P Å .04, respectively). Whether a greater incidence of In this study, the proportion of patients receiving 0.3% or 1% cidofovir gel who achieved a complete or good response was complete or good response would be achieved with ú5 days of consecutive daily dosing cannot be determined from the similar (55% vs. 44%), as was the median time to this response (27 vs. 36 days). However, those receiving 1% cidofovir gel present study.
The virologic results from this study are consistent with had a significantly shorter median time to negative viral culture than did those receiving 0.3% gel (4 vs. 2 days; P Å .03). the potent and prolonged in vitro antiviral effects previously described for cidofovir [6, 7, 9] , in that cessation of viral shedAcyclovir-unresponsive mucocutaneous HSV infection can be a painful and debilitating condition [1] . The inclusion of a ding was both more rapid and more frequent than in patients receiving placebo. The instances of discordance between lesion group of patients in this study receiving treatment with placebo documents that these lesions are unremitting in AIDS patients healing and cessation of viral shedding, as described, are with-
